相似文献
1
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
J Clin Pharmacol. 2010 Jun;50(6):714-20. doi: 10.1177/0091270009353031. Epub 2010 Jan 26.
2
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):513-9. doi: 10.1097/QAI.0b013e318183a425.
3
Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
Br J Clin Pharmacol. 2010 Jul;70(1):126-31. doi: 10.1111/j.1365-2125.2010.03661.x.
4
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
J Clin Pharmacol. 2008 Apr;48(4):464-74. doi: 10.1177/0091270008314254. Epub 2008 Feb 20.
5
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.
Clin Pharmacol Ther. 2012 Dec;92(6):771-7. doi: 10.1038/clpt.2012.186. Epub 2012 Nov 14.
6
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Pharmacogenetics. 2004 Apr;14(4):225-38. doi: 10.1097/00008571-200404000-00002.
7
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Drug Metab Dispos. 2000 Oct;28(10):1176-83.
8
Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.
Br J Clin Pharmacol. 2012 Dec;74(6):999-1004. doi: 10.1111/j.1365-2125.2012.04304.x.
9
Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.
Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):57-63. doi: 10.1007/s13318-011-0065-6. Epub 2011 Sep 17.
10
The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Drug Metab Dispos. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13.
引用本文的文献
1
Chirality of antidepressive drugs: an overview of stereoselectivity.
Asian Biomed (Res Rev News). 2022 Apr 29;16(2):55-69. doi: 10.2478/abm-2022-0008. eCollection 2022 Apr.
2
The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.
Pharmacol Res Perspect. 2019 Apr 26;7(3):e00475. doi: 10.1002/prp2.475. eCollection 2019 Jun.
3
Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 1;1017-1018:101-113. doi: 10.1016/j.jchromb.2016.02.032. Epub 2016 Feb 27.
4
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.
Semin Dial. 2015 Jul-Aug;28(4):325-9. doi: 10.1111/sdi.12374. Epub 2015 Apr 8.
5
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.
Pharmacotherapy. 2014 Feb;34(2):114-22. doi: 10.1002/phar.1347. Epub 2013 Sep 6.
本文引用的文献
1
Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.
Pharmacotherapy. 2009 Jan;29(1):7-16. doi: 10.1592/phco.29.1.7.
2
Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
Eur J Clin Pharmacol. 2009 Apr;65(4):403-9. doi: 10.1007/s00228-008-0594-3. Epub 2008 Dec 9.
3
Downregulation of hepatic acetylation of drugs in chronic renal failure.
J Am Soc Nephrol. 2008 Jul;19(7):1352-9. doi: 10.1681/ASN.2007090974. Epub 2008 Apr 16.
4
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
Clin Pharmacol Ther. 2008 Jun;83(6):898-903. doi: 10.1038/clpt.2008.59. Epub 2008 Apr 2.
5
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
J Clin Pharmacol. 2008 Apr;48(4):464-74. doi: 10.1177/0091270008314254. Epub 2008 Feb 20.
6
Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Pharm Res. 2008 Jun;25(6):1405-11. doi: 10.1007/s11095-008-9535-1.
7
Prevalence of chronic kidney disease in the United States.
JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038.
8
Effects of chronic renal failure on liver drug transporters.
Drug Metab Dispos. 2008 Jan;36(1):124-8. doi: 10.1124/dmd.107.018192. Epub 2007 Oct 16.
9
Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 15;857(1):67-75. doi: 10.1016/j.jchromb.2007.07.007. Epub 2007 Jul 10.
10
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.
Br J Clin Pharmacol. 2007 Aug;64(2):165-73. doi: 10.1111/j.1365-2125.2007.02866.x. Epub 2007 Mar 1.
Zotero 插件